📊 ABCL Key Takeaways
Is AbCellera Biologics Inc. (ABCL) a Good Investment?
AbCellera is a pre-commercial biotech company burning significant cash with negative margins across all profitability measures, though revenue growth of 160.6% YoY demonstrates early commercial traction. The company has adequate liquidity (11.3x current ratio, $128.5M cash) to fund operations, but the path to profitability remains unclear with operating losses of $217.1M and free cash flow of -$174.1M on just $75.1M in revenue.
AbCellera shows strong top-line momentum and an exceptionally strong balance sheet, with high liquidity, no meaningful leverage, and nearly $967M of equity supporting continued investment. However, the business remains deeply unprofitable, with very weak operating efficiency and heavily negative free cash flow, so the current fundamentals support patience rather than conviction until revenue growth translates into durable margin improvement.
Why Buy AbCellera Biologics Inc. Stock? ABCL Key Strengths
- Exceptional revenue growth of 160.6% YoY demonstrates market demand and successful commercialization of antibody discovery platform
- Strong balance sheet with $966.9M stockholders equity and negligible debt (0.00x debt/equity ratio)
- Excellent liquidity position with 11.32x current ratio providing 12+ months of cash runway at current burn rates
- Revenue grew 160.6% year over year, indicating strong commercial or milestone-driven momentum
- Balance sheet is robust with $128.51M in cash, a current ratio above 11x, and no meaningful debt burden
- Low leverage and substantial equity provide flexibility to absorb continued operating losses and fund development
ABCL Stock Risks: AbCellera Biologics Inc. Investment Risks
- Severe cash burn with -$174.1M free cash flow and -$131.3M operating cash flow unsustainable without additional capital or significant revenue acceleration
- Profitability metrics deeply negative (operating margin -289%, net margin -194.9%) with no clear path to breakeven visible in current trajectory
- Business model economics uncertain with negative gross margins implied, suggesting current revenue does not cover direct costs of delivery
- Operating losses of $217.1M represent 2.9x annual revenue, indicating massive scaling required before profitability achievable
- Operating margin of -289.0% and net margin of -194.9% show the business model is not yet generating scalable profitability
- Free cash flow of -$174.07M and negative operating cash flow indicate ongoing cash burn
- Revenue quality may be uneven if growth is driven by non-recurring collaboration or milestone payments rather than repeatable product economics
Key Metrics to Watch
- Quarterly revenue growth rates and customer concentration to validate sustainability of 160% growth
- Gross margin expansion as volume scales and manufacturing efficiency improves
- Monthly cash burn rate and projected runway to breakeven or next capital requirement
- Operating expense reduction through operational leverage as revenue scales
- Operating cash burn and free cash flow trend
- Revenue durability and operating margin improvement
AbCellera Biologics Inc. (ABCL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.32x current ratio provides a solid financial cushion.
ABCL Profit Margin, ROE & Profitability Analysis
ABCL vs Healthcare Sector: How AbCellera Biologics Inc. Compares
How AbCellera Biologics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AbCellera Biologics Inc. Stock Overvalued? ABCL Valuation Analysis 2026
Based on fundamental analysis, AbCellera Biologics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AbCellera Biologics Inc. Balance Sheet: ABCL Debt, Cash & Liquidity
ABCL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AbCellera Biologics Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
ABCL Revenue Growth, EPS Growth & YoY Performance
ABCL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.5M | -$34.7M | $-0.17 |
| Q2 2025 | $7.3M | -$34.7M | $-0.12 |
| Q1 2025 | $4.2M | -$40.6M | $-0.14 |
| Q3 2024 | $6.5M | -$28.6M | $-0.10 |
| Q2 2024 | $7.3M | -$30.5M | $-0.11 |
| Q1 2024 | $10.0M | -$40.1M | $-0.14 |
| Q3 2023 | $6.6M | -$6.8M | $0.08 |
| Q2 2023 | $10.1M | -$6.8M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AbCellera Biologics Inc. Dividends, Buybacks & Capital Allocation
ABCL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AbCellera Biologics Inc. (CIK: 0001703057)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABCL
What is the AI rating for ABCL?
AbCellera Biologics Inc. (ABCL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABCL's key strengths?
Claude: Exceptional revenue growth of 160.6% YoY demonstrates market demand and successful commercialization of antibody discovery platform. Strong balance sheet with $966.9M stockholders equity and negligible debt (0.00x debt/equity ratio). ChatGPT: Revenue grew 160.6% year over year, indicating strong commercial or milestone-driven momentum. Balance sheet is robust with $128.51M in cash, a current ratio above 11x, and no meaningful debt burden.
What are the risks of investing in ABCL?
Claude: Severe cash burn with -$174.1M free cash flow and -$131.3M operating cash flow unsustainable without additional capital or significant revenue acceleration. Profitability metrics deeply negative (operating margin -289%, net margin -194.9%) with no clear path to breakeven visible in current trajectory. ChatGPT: Operating margin of -289.0% and net margin of -194.9% show the business model is not yet generating scalable profitability. Free cash flow of -$174.07M and negative operating cash flow indicate ongoing cash burn.
What is ABCL's revenue and growth?
AbCellera Biologics Inc. reported revenue of $75.1M.
Does ABCL pay dividends?
AbCellera Biologics Inc. does not currently pay dividends.
Where can I find ABCL SEC filings?
Official SEC filings for AbCellera Biologics Inc. (CIK: 0001703057) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABCL's EPS?
AbCellera Biologics Inc. has a diluted EPS of $-0.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABCL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AbCellera Biologics Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ABCL stock overvalued or undervalued?
Valuation metrics for ABCL: ROE of -15.1% (sector avg: 15%), net margin of -194.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ABCL stock in 2026?
Our dual AI analysis gives AbCellera Biologics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABCL's free cash flow?
AbCellera Biologics Inc.'s operating cash flow is $-131.3M, with capital expenditures of $42.8M. FCF margin is -231.7%.
How does ABCL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -194.9% (avg: 12%), ROE -15.1% (avg: 15%), current ratio 11.32 (avg: 2).